The content on this site is intended for healthcare professionals only
At a press conference at ESMO 2014, Dr Rapoport presents the results of his phase 3 trial which looked at the use of rolapitant for the prevention of chemotherapy-induced nausea and vomiting.
Read the news story and watch the interview for more.
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
The Southeast Asian Breast Cancer Symposium; background, aims and successes
War in Ukraine: The Global Medical Knowledge Alliance's response to improving cancer care
OncoAlert Round Up for August 4th - 10th, 2023
NSIA and BVGH aim to improve patient outcomes and access to quality cancer care
Management of prostate cancer in Africa: Looking to the future
Time toxicity: the burden on cancer patients
The current status of multiple myeloma diagnosis and treatment
